Latest Regulatory Milestones News

Astral Resources has secured a pivotal Land Use Agreement with the Marlinyu Ghoorlie Native Title Claim Group, clearing the way for funded development of the Think Big Gold deposit in Western Australia.

The ACCC has approved Cuscal Limited’s acquisition of Indue Limited, concluding the deal won’t significantly reduce competition in payment facilitation services. The decision highlights ongoing industry consolidation balanced by multiple alternative providers and technological shifts.

Memphasys secures a follow-up order for its Felix™ sperm selection cartridges from a leading Japanese fertility clinic, marking growing adoption in one of the world’s largest IVF markets and signaling a strategic shift to direct sales.

E79 Gold Mines has reported outstanding high-grade copper and gold assay results from its Mountain Home Project in the Northern Territory, significantly expanding the known mineralised area and setting the stage for drilling in 2026.

ACDC Metals reports compelling mineralogy results from its Goschen Central project, highlighting elevated rare earth element grades that reinforce its economic potential. The announcement coincides with strategic momentum from the Australia-US Critical Minerals Framework, positioning the project as a key player in global supply chains.

Island Pharmaceuticals secures FDA confirmation that regulatory feedback on Galidesivir’s approval pathway will arrive on schedule, underscoring the drug’s strategic importance amid US government disruptions.

Woodside Energy has raised its 2025 production guidance following a 1% increase in quarterly output, while progressing key projects like Scarborough and Beaumont New Ammonia on schedule. The company also secured long-term LNG supply deals and received critical regulatory approvals.

Ballard Mining’s September quarter report highlights promising drilling results at its Mt Ida Gold Project and secures final approvals for a 2.0 Mtpa processing plant, underpinning its development ambitions.

Imagion Biosystems has made significant strides toward filing an IND application for its MagSense® HER2 breast cancer imaging agent, supported by positive FDA feedback and a recent $3.5 million capital raise to fund upcoming clinical trials.

BPH Global Ltd reports a steady increase in Indonesian seaweed sales alongside securing a crucial export licence, setting the stage for international market entry.

Southern Palladium has raised A$20 million through a strategic share placement to accelerate its Bengwenyama PGM project, positioning the company for key milestones including a Final Investment Decision in 2026.

Neuren Pharmaceuticals has secured FDA Fast Track designation for its drug NNZ-2591 targeting Phelan-McDermid syndrome, accelerating its path through clinical development. This milestone underscores the urgent need for treatments in rare neurodevelopmental disorders.